HOW XOLAIR MAY WORK

How XOLAIR may work in CSU

XOLAIR helped people with itch and hive symptoms
in the clinical study results.

HOW XOLAIR MAY WORK

How XOLAIR may work in CSU

 XOLAIR helped people with itch and hive symptoms in the clinical study results.

To understand how XOLAIR may work in helping to reduce itch severity and number of hives, you should know about mast cells, histamine, and immunoglobulin E (IgE)

Graphic outlining step by step process of how Xolair® (omalizumab) may work to help reduce itch severity and number of hives including the following text: IgE is a substance made by the body that attaches to receptors on mast cells, triggering them to release histamine and other inflammatory substances under certain conditions. Mast cells are cells found in almost all tissues of the body, such as skin. They play an important role in chronic hives with no known cause by releasing certain inflammatory substances. Histamine is a chemical in your body that causes inflammation, leading to hives and itching associated with chronic hives. XOLAIR was designed to bind to IgE to limit its ability to attach to mast cells, which reduces the release of inflammatory substances and IgE receptors on the surface of mast cells. How this specifically improves the symptoms of chronic hives is not clear.

XOLAIR dosing and frequency

XOLAIR is given by an injection just under the skin (subcutaneous injection) every 4 weeks. This can be done by your healthcare provider, in a healthcare setting—or in the comfort of your own home through self-injection. Please connect with your doctor, who will determine whether you are an appropriate candidate for self injection.


XOLAIR at a glance

Icon with number 12 and plus sign

XOLAIR is for people 12 years of age and older with chronic spontaneous urticaria (CSU) not controlled by H1 antihistamines.

Icon with arrow pointing down

XOLAIR may help reduce itch and hives. See clinical trial data.

Icon of box with checkmark inside of it

XOLAIR is the first FDA-approved biologic treatment for chronic hives with no known cause.

Icon with number 12 and plus sign

XOLAIR is for people 12 years of age and older with chronic spontaneous urticaria (CSU) not controlled by H1 antihistamines.

Icon with arrow pointing down

XOLAIR may help reduce itch and hives. See clinical trial data.

Icon of box with checkmark inside of it

XOLAIR is the first FDA-approved biologic treatment for chronic hives with no known cause.
 


Image of a Xolair® (omalizumab) single-dose prefilled injection syringe and its box label

Not actual size

The XOLAIR prefilled syringe and autoinjector is

AVAILABLE FOR
SELF-INJECTION

Ask your doctor if self-injection is right for you.

 

Learn more

You’ve got a partner in this

Logo of the Xolair® (Omalizumab) Support for You program

From diagnosis to treatment, your journey with chronic hives is unique.

The Support For You program is designed with YOU in mind.

Take advantage of free support resources that can help you at every step—from talking to a specialist to getting started to potentially saving on XOLAIR.

IMPORTANT SAFETY INFORMATION & INDICATION

What is XOLAIR?

XOLAIR® (omalizumab) for subcutaneous use is an injectable prescription medicine used to treat chronic spontaneous urticaria (CSU, previously referred to as chronic idiopathic urticaria (CIU), chronic hives without a known cause) in people 12 years of age and older who continue to have hives that are not controlled with H1 antihistamine treatment. It is not known if XOLAIR is safe and effective in people with CSU under 12 years of age.

XOLAIR is not used to treat other forms of hives.

What is the most important information I should know about XOLAIR?

Severe allergic reaction. A severe allergic reaction called anaphylaxis can happen when you receive XOLAIR. The reaction can occur after the first dose, or after many doses. It may also occur right after a XOLAIR injection or days later. Anaphylaxis is a life-threatening condition and can lead to death. Go to the nearest emergency room right away if you have any of these symptoms of an allergic reaction:

  • wheezing, shortness of breath, cough, chest tightness, or trouble breathing
  • low blood pressure, dizziness, fainting, rapid or weak heartbeat, anxiety, or feeling of “impending doom”
  • flushing, itching, hives, or feeling warm
  • swelling of the throat or tongue, throat tightness, hoarse voice, or trouble swallowing

Your healthcare provider will monitor you closely for symptoms of an allergic reaction while you are receiving XOLAIR and for a period of time after treatment is initiated. Your healthcare provider should talk to you about getting medical treatment if you have symptoms of an allergic reaction.

Do not receive and use XOLAIR if you are allergic to omalizumab or any of the ingredients in XOLAIR.

Before receiving XOLAIR, tell your healthcare provider about all of your medical conditions, including if you:
  • have a latex allergy or any other allergies (such as food allergy or seasonal allergies). The needle cap on the XOLAIR prefilled syringe contains a type of natural rubber latex.
  • have ever had a severe allergic reaction called anaphylaxis
  • have or have had a parasitic infection
  • have or have had cancer
  • are pregnant or plan to become pregnant. It is not known if XOLAIR may harm your unborn baby.
  • are breastfeeding or plan to breastfeed. It is not known if XOLAIR passes into your breast milk. Talk with your healthcare provider about the best way to feed your baby while you receive and use XOLAIR.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How should I receive and use XOLAIR?
  • When starting treatment, XOLAIR should be given by your healthcare provider in a healthcare setting.
  • Do not try to inject XOLAIR until you have been shown the right way to give XOLAIR prefilled syringe or autoinjector injections by a healthcare provider. Use XOLAIR exactly as prescribed by your healthcare provider.
  • The XOLAIR autoinjector (all doses) is intended for use only in adults and adolescents aged 12 years and older. For children 12 years of age and older, XOLAIR prefilled syringe or autoinjector may be self-injected under adult supervision.
  • See the detailed Instructions for Use that comes with XOLAIR for information on the right way to prepare and inject XOLAIR.
  • XOLAIR is given in 1 or more injections under the skin (subcutaneous), 1 time every 4 weeks.
  • In people with chronic hives, a blood test is not necessary to determine the dose or dosing frequency.
  • Do not decrease or stop taking any of your other hive medicine unless your healthcare providers tell you to.
  • You may not see improvement in your symptoms right away after XOLAIR treatment.
  • If you inject more XOLAIR than prescribed, call your healthcare provider right away.
What are the possible side effects of XOLAIR?
XOLAIR may cause serious side effects, including:
  • Cancer. Cases of cancer were observed in some people who received XOLAIR.
  • Fever, muscle aches, and rash. Some people get these symptoms 1 to 5 days after receiving a XOLAIR injection. If you have any of these symptoms, tell your healthcare provider.
  • Parasitic infection. Some people who are at a high risk for parasite (worm) infections, get a parasite infection after receiving XOLAIR. Your healthcare provider can test your stool to check if you have a parasite infection.
  • Heart and circulation problems. Some people who receive XOLAIR have had chest pain, heart attack, blood clots in the lungs or legs, or temporary symptoms of weakness on one side of the body, slurred speech, or altered vision. It is not known whether these are caused by XOLAIR.

The most common side effects of XOLAIR in people with chronic spontaneous urticaria: nausea, headaches, swelling of the inside of your nose, throat or sinuses, cough, joint pain, and upper respiratory tract infection.

These are not all the possible side effects of XOLAIR. Call your doctor for medical advice about side effects.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555 or Novartis Pharmaceuticals Corporation at (888) 669-6682.

Please see full Prescribing Information, including Medication Guide, for additional Important Safety Information and Instructions for Use.